Annora Pharma Private Limited — China drug registrations and re-registration deadlines
8 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2029-11-26.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20250060 | Oxcarbazepine Tablets 奥卡西平片 | 2030-05-26 | 2029-11-26 |
| 国药准字HJ20250061 | Oxcarbazepine Tablets 奥卡西平片 | 2030-05-26 | 2029-11-26 |
| 国药准字HJ20250062 | Oxcarbazepine Tablets 奥卡西平片 | 2030-05-26 | 2029-11-26 |
| 国药准字HJ20250122 | Deferasirox Tablets 地拉罗司片 | 2030-10-13 | 2030-04-13 |
| 国药准字HJ20250123 | Deferasirox Tablets 地拉罗司片 | 2030-10-13 | 2030-04-13 |
| 国药准字HJ20250124 | Deferasirox Tablets 地拉罗司片 | 2030-10-13 | 2030-04-13 |
| 国药准字HJ20260037 | Ivabradine Hydrochloride Tablets 盐酸伊伐布雷定片 | 2031-04-13 | 2030-10-13 |
| 国药准字HJ20260038 | Ivabradine Hydrochloride Tablets 盐酸伊伐布雷定片 | 2031-04-13 | 2030-10-13 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.